2. Home
  3. Overview
  4. Stem Cell Treatment for Neurodegenerative Diseases
  5. Multiple Sclerosis (MS)

Stem Cell Therapy for Multiple Sclerosis (MS)

Multiple sclerosis is a disease of the central nervous system involving the brain and spinal cord. It is caused by an immune-mediated attack on the myelin sheath, the protective layer around nerve fibres.

The myelin sheath works much like the insulation layer of a cable. It helps protect nerve fibres and supports normal communication within the nervous system. As such, damage to this protective layer can impair the normal function of affected nerves, with symptoms varying widely between patients.

At ANOVA IRM in Offenbach, Germany, stem cell-based therapy is being explored as an experimental regenerative treatment option for selected MS patients. ANOVA’s MS treatment approach is reviewed alongside established treatment options and focuses on autologous Mesenchymal Stem Cell Secretome / Exosome therapy, also known as MSEC therapy, a cell-free approach based on factors released by mesenchymal stem cells.

On this page, you will find more information about ANOVA’s stem cell-based MS treatments. Treatment remains experimental, outcomes vary, and improvement cannot be guaranteed. An individual medical review is required to determine eligibility.

Multiple Sclerosis Treatment Overview

On this page, you can jump directly to the following topics:

Patients may be considered for treatment in selected cases involving:

  • Early-to-mid-stage multiple sclerosis
  • Relapsing-remitting MS, where medically appropriate
  • Primary progressive MS, where medically appropriate
  • Secondary progressive MS, where medically appropriate
  • Persistent symptoms despite standard care

Stem Cell Therapy for Multiple Sclerosis at ANOVA IRM

Stem cell therapy is not a replacement for established MS treatment. Disease-modifying therapies, physiotherapy, rehabilitation, muscle relaxants, and symptom-focused therapies remain standard components of MS treatment plans.

These conventional MS treatments can help patients by:

  • Reducing inflammatory disease activity
  • Slowing disease progression
  • Managing relapses and symptoms
  • Supporting mobility, function, and quality of life

However, these therapies often have limitations. In many cases, they do not fully restore lost neurological function or repair damage that has already occurred.

This has led to continued research into experimental regenerative medicine options, including stem cell-based therapies. At ANOVA IRM, MSEC therapy is reviewed for selected MS patients alongside established treatment options as part of a personalized treatment concept.

Diagram comparing healthy myelin with damaged myelin in multiple sclerosis.
Healthy and damaged myelin

Can Stem Cell Therapy Help Multiple Sclerosis?

Stem cell therapy for multiple sclerosis is still considered experimental. It is not an established cure for MS, and outcomes vary from patient to patient.

This approach is being studied because MS involves several mechanisms, including immune dysfunction, neuroinflammation, myelin damage, and possible axonal injury. These processes can contribute to attacks on the myelin sheath, which may disrupt normal nerve signalling.

For this reason, research into stem cell-based therapies for MS has explored areas targeting these mechanisms, such as:

  • Immune modulation and inflammation
  • Neuroinflammation-related pathways
  • Neuroprotection of affected nerve tissue
  • Cell survival and repair-related signalling
  • Remyelination research
  • Axonal injury and nerve tissue support

This is why many modern stem cell treatment concepts are not based on replacing damaged nerve cells. Instead, research increasingly focuses on mesenchymal stem cells and the bioactive molecules they release, which may communicate with surrounding cells and tissues.

This stem cell research background, including findings from small external clinical trials, helps explain ANOVA IRM’s focus on MSEC therapy for selected MS patients.

These findings should be understood as research findings, not guaranteed treatment outcomes. Evidence is still limited, and an individual medical review is required to determine whether treatment may be appropriate.

Microscopic stem cell culture image related to MSC therapy and regenerative medicine research.
Stem cell culture

ANOVA IRM Treatment Approach for Multiple Sclerosis

At ANOVA IRM, stem cell-based therapy for multiple sclerosis is reviewed within a controlled medical framework in a regulated German medical setting.

ANOVA employs autologous treatment concepts, meaning therapies are produced from the patient’s own biological material rather than donor-derived products. This supports biological compatibility while avoiding risks associated with donor-derived approaches.

For MS, ANOVA’s treatment approach focuses on Mesenchymal Stem Cell Secretome / Exosome therapy, also known as MSEC therapy. Because MS affects patients differently, ANOVA reviews each case individually based on disease stage, current therapies, diagnostic findings, and benefit-risk profile.

What Therapeutic Outcomes Can Be Expected?

Stem cell-based therapy for MS remains experimental, and outcomes vary from patient to patient. Treatment goals are reviewed individually and should not be understood as guaranteed results.

Potential treatment goals or monitoring areas may include:

  • Immune modulation and inflammatory activity
  • Neuroprotection and cell survival
  • Repair-related signalling and remyelination research
  • Monitoring of new lesion activity or relapse activity
  • Vision-related measures, symptoms, and quality of life

Treatment cannot guarantee remyelination, disease stabilization, symptom relief, relapse reduction, or reversal of neurological damage.

Potency Hypothesis of Stem Cell Therapies

Stem cells and their secretome may communicate with immune cells involved in inflammation. In MS, this is relevant because immune overactivity contributes to attacks on the myelin sheath.

The stem cell secretome contains soluble factors involved in cell-to-cell communication, including growth factors, cytokines, proteins, miRNAs, exosomes, and microvesicles. This activity is often described as paracrine signalling.

The goal is not to replace damaged cells. Instead, ANOVA’s MS treatment rationale focuses on the potential of stem cell-derived factors to influence immune activity, inflammatory signalling, cell survival, and repair-related tissue responses.

Illustration of immune cells damaging myelin in multiple sclerosis autoimmune disease activity.
Immune activity in MS

MSEC / Mesenchymal Stem Cell Secretome / Exosome Therapy

Mesenchymal Stem Cell Secretome, or MSEC, is a cell-free regenerative treatment. Instead of relying on the direct transplantation of living stem cells, MSEC uses bioactive molecules released by mesenchymal stem cells, including exosomes, cytokines, proteins, growth factors, miRNAs, and microvesicles.

At ANOVA IRM, MSEC is produced from the patient’s own adipose-derived mesenchymal stem cells. These cells are harvested from abdominal fat through a limited mini-liposuction procedure under light sedation.

A key advantage of MSEC is that it can be frozen and stored for repeated use. This allows ANOVA IRM to produce multiple injection doses from one liposuction, which can then be administered over a longer treatment period.

Because MS is a chronic disease and is not currently curable, ANOVA recommends longer-term treatment planning with repeated MSEC applications. Depending on the treatment plan, ANOVA IRM may produce 10–20 injection doses from one liposuction. The secretome shelf life is two years.

MSEC treatment remains experimental and is not a cure for MS. Patients should plan for repeated travel to Offenbach, Germany if they intend to complete the planned applications.

Learn more about our Secretome / Exosome therapies.

Diagram of MSC therapy showing mesenchymal stem cell secretome, exosomes, cytokines, proteins, miRNA, and microvesicles.
MSC secretome / exosome signalling

Who May Be a Candidate for MS Stem Cell Therapy?

As an experimental treatment, stem cell-based therapy is not suitable for every multiple sclerosis patient.

ANOVA IRM generally focuses on early-to-mid-stage MS, where the physician believes the potential benefit-risk profile may support treatment with autologous MSEC / Secretome therapy. An individual medical review is required to determine whether treatment may be appropriate.

Patients who may be considered include those with:

  • Early-to-mid-stage multiple sclerosis
  • Relapsing-remitting MS, primary progressive MS, or secondary progressive MS, where medically appropriate
  • Persistent MS symptoms, functional limitations, or MS disease activity despite standard care
  • Medical suitability for light sedation and adipose tissue collection through mini-liposuction
  • Ability to breathe independently
  • Ability to breathe comfortably while lying down
  • Ability to travel to Offenbach, Germany, for evaluation and treatment

ANOVA IRM does not treat patients when the following contraindications apply:

  • Active cancer within the last two years
  • Not being of legal age
  • Pregnancy or lactation
  • Inability to breathe independently or ventilator dependence
  • Difficulty breathing while lying down
  • Dysphagia, or extreme difficulty swallowing
  • Psychiatric disorder
  • Active infectious disease, including hepatitis A, B, or C, HIV, syphilis, or other active infections

A physician must determine whether the possible benefits outweigh the risks for the individual patient. Applying for evaluation does not mean a patient will automatically qualify for treatment.

Therapy Workflow for Early-to-Mid-Stage Multiple Sclerosis

What to Expect From the Treatment Process

 

Step 1: Remote MS Inquiry Review

 

Before treatment planning can begin, ANOVA IRM must determine whether the patient may be a candidate for MS stem cell therapy. For international patients, this process usually starts remotely before any travel to Germany is required.

Patients can begin by submitting the contact form. They then receive MS-specific information about ANOVA’s treatment approach, including the experimental nature of MSEC therapy and possible next steps.

If the patient would like to continue, ANOVA’s patient care team will explain what information is needed and help arrange the next stage of communication. This may include medical records, current MS therapies, recent diagnostic findings, and other relevant health information.

Patient care can also help schedule a call with an ANOVA physician to determine whether the patient should proceed with in-person eligibility testing and treatment planning.

 

Step 2: Pre-Treatment Eligibility Testing and Day-One Confirmation

 

Once initial suitability is confirmed through a consultation, ANOVA IRM generally recommends that patients complete preliminary bloodwork in their home country before travelling to Germany. This helps check for exclusion criteria such as HIV, hepatitis A, B, or C, syphilis, or other active infectious diseases. Patients with certain medical or substance-use risk factors may also be excluded.

If no exclusion criteria are identified in the preliminary results, patients can then travel to ANOVA IRM in Offenbach, Germany, for the planned treatment visit. On the first day at ANOVA IRM, the required bloodwork is repeated according to German medical requirements before the patient’s own cells can be used in the laboratory.

Mini-liposuction for adipose tissue collection is usually planned for the following day.

 

Step 3: MSEC Treatment Protocol Selection

 

An MSEC treatment protocol is chosen with the patient according to their availability. A preliminary treatment plan will be discussed prior to travel to Germany, with the exact schedule depending on MS stage, symptoms, planned number of doses, travel needs, and physician assessment.

For MS, treatment planning may involve one of three standard protocol patterns:

  • Boost + Balanced: Three doses are administered during the first treatment visit, followed by one dose every three months. This may be considered for patients with high travel readiness.
  • Balanced-Boost: Ten doses are administered over four visits, with visits usually spaced six months apart. This is often more practical for international patients or patients with limited travel availability.
  • Intense Balanced-Boost: Ten doses are administered over four visits, with visits usually spaced three months apart. This may be considered for patients for whom a more intensive treatment schedule is medically appropriate.

Before treatment begins, ANOVA IRM reviews the planned number of MSEC applications, cost estimate, travel needs, and scheduling options with the patient. Applications can be scheduled flexibly within the two-year secretome shelf life.

 

Step 4: Mini-Liposuction and MSEC Production

 

Once the physician clears the patient to proceed with the treatment plan, adipose tissue is collected through a limited mini-liposuction procedure. This is usually performed under light sedation during the same Offenbach treatment trip as the eligibility work-up.

Mesenchymal stem cells are isolated from the adipose tissue and used to produce the stem cell secretome. The final secretome product no longer contains living MSCs.

The product undergoes enrichment and quality control before being stored for treatment. MSEC applications usually begin approximately four weeks after isolation.

 

Step 5: MSEC Applications Over Time

 

Patients return to ANOVA IRM in Offenbach for MSEC applications according to the selected treatment protocol.

Because MS is chronic and not currently curable, ANOVA IRM recommends repeated MSEC applications for eligible MS patients as part of a longer-term treatment plan.

Patients who live closer to Germany may return for applications at regular intervals. For patients travelling from distant regions, applications may be scheduled differently to reduce the number of trips.

The secretome shelf life is two years, and available doses must be administered within that period.

 

Treatment Timeline and Travel Requirements

Initial analysis and counselling can usually begin remotely, without travelling to Offenbach. This stage may take two weeks to several months, depending on patient availability and scheduling.

The main MS treatment timeline is usually built around three stages:

  • Bloodwork and mini-liposuction: Patients travel to ANOVA IRM in Offenbach for bloodwork, medical review, and any required pre-treatment diagnostics. If treatment can proceed, adipose tissue harvesting usually takes place the following day. This visit usually requires approximately two consecutive days in Offenbach.
  • Secretome production: After harvesting, the stem cell secretome is produced and quality-controlled. This process takes approximately four weeks.
  • MSEC applications: Patients return to Offenbach for MSEC applications according to the selected treatment protocol. Because MS is chronic and not currently curable, repeated applications may be considered for selected patients.

The schedule may be adjusted based on medical needs, travel distance, available doses, and the selected treatment protocol. Patients should expect repeated travel to Offenbach if ongoing MSEC applications are recommended.

Cost of Stem Cell Therapy for Multiple Sclerosis

The cost of stem cell therapy for multiple sclerosis depends on the patient’s disease stage, selected treatment protocol, number of applications, diagnostics, and sedation or anaesthesia needs.

MS treatment costs generally exceed €10,000 and vary depending on the individual treatment plan. Before treatment begins, ANOVA IRM provides an individual cost estimate so patients can understand the expected cost before deciding whether to proceed.

Does Health Insurance Cover the Therapy Costs?

Stem cell-based therapy for MS is experimental and is generally not covered by health insurance.

Patients should expect to pay for treatment themselves unless their insurer confirms otherwise. Insurance coverage should not be assumed.

Why Choose ANOVA IRM for Multiple Sclerosis Treatment?

  • Autologous MSEC therapy: ANOVA’s MS approach focuses on Mesenchymal Stem Cell Secretome / Exosome therapy produced from the patient’s own biological material.
  • Controlled treatment in Germany: Treatment takes place at ANOVA IRM, a private German clinic for regenerative medicine in Offenbach, near Frankfurt am Main airport.
  • Regulated treatment environment and quality controls: Treatment takes place in Germany within a controlled medical setting, with product quality controls before treatment.
  • Standardized medical procedures: ANOVA uses standardized procedures for stem cell isolation, processing, diagnostic work-up, and treatment planning.
  • Individual medical review: Each patient is reviewed before treatment is recommended, with clear expectations around eligibility, timeline, travel requirements, cost, and experimental status.

Request a Medical Evaluation

Find out whether stem cell-based therapy may be suitable for your multiple sclerosis.

ANOVA IRM can begin with a remote medical review before you travel to Germany. Our patient care team can explain the next steps and help arrange a physician consultation.

Because stem cell-based therapy for MS is experimental, treatment can only be recommended after an individual medical review and benefit-risk assessment. ANOVA IRM cannot treat children or pregnant patients, and other medical factors may also exclude a patient from treatment.

Contact us to begin your remote medical evaluation.

Frequently Asked Questions About Stem Cell Therapy for Multiple Sclerosis

Is stem cell therapy for multiple sclerosis available at ANOVA IRM?

Yes. ANOVA IRM reviews selected multiple sclerosis patients for stem cell-based therapy after medical evaluation. The MS treatment approach focuses on autologous Mesenchymal Stem Cell Secretome / Exosome therapy, also known as MSEC therapy.

Can stem cell therapy cure multiple sclerosis?

No. Stem cell therapy is not an established cure for MS, and treatment cannot guarantee symptom improvement, disease stabilization, relapse reduction, remyelination, or neurological recovery. At ANOVA IRM, stem cell-based therapy for MS is considered experimental and can only be recommended after individual medical review.

Who may be a candidate for MS stem cell therapy?

Suitability depends on MS type, disease stage, current symptoms, current therapies, medical history, diagnostic findings, overall health, and ability to travel for treatment. ANOVA IRM generally focuses on selected patients with early-to-mid-stage MS who may be medically suitable for autologous MSEC therapy.

What types of MS may be considered for treatment?

Patients with relapsing-remitting MS, primary progressive MS, or secondary progressive MS may be considered for treatment where medically appropriate. Eligibility is not based on MS type alone. ANOVA IRM also considers disease stage, symptoms, overall health, treatment goals, ability to travel, and medical suitability for autologous MSEC therapy.

What is MSEC / Stem Cell Secretome therapy?

MSEC stands for Mesenchymal Stem Cell Secretome. It is a cell-free therapy that uses bioactive molecules released by mesenchymal stem cells, including exosomes and other signalling substances, rather than directly transplanting living stem cells.

How is MSEC different from aHSCT?

MSEC therapy and autologous hematopoietic cell transplantation, or aHSCT, are different treatment approaches. aHSCT is designed to reset parts of the immune system using chemotherapy and stem cell transplantation. ANOVA’s MS approach focuses on cell-free MSEC / Secretome therapy produced from the patient’s own adipose-derived mesenchymal stem cells.

How long does treatment take?

The timeline depends on the patient’s treatment plan and scheduling preferences. Initial review can usually begin remotely. Patients then travel to Offenbach for mini-liposuction to collect adipose tissue. MSEC production and quality control usually take approximately four weeks after isolation. Patients then return to Offenbach for applications according to the planned application schedule.

How much does stem cell therapy for multiple sclerosis cost?

The cost depends on the patient’s disease stage, selected treatment protocol, number of MSEC applications, diagnostics, and sedation or anaesthesia needs. MS treatment costs are generally well above €10,000. ANOVA IRM provides an individual cost estimate before treatment begins.

Does health insurance cover stem cell therapy for MS?

Stem cell-based therapy for MS is experimental and is generally not covered by health insurance. Patients should expect to pay for treatment themselves unless their insurer confirms otherwise.

Can international patients apply for treatment?

Yes. International patients can usually begin with a remote inquiry review before travelling to Germany. ANOVA IRM’s patient care team can explain what information is needed and help arrange the next steps for physician consultation, eligibility work-up, and treatment planning.

References and Literature - Stem Cell-based Therapies for Multiple Sclerosis

  • Fox, R. J. & Ransohoff, R. M. New directions in MS therapeutics: vehicles of hope. Trends Immunol. 2004 25(12):632-6.
  • Caplan, A. I. Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. J Cell Physiol. 2007 213(2):341-7.
  • Gianvito Martino, Robin J. M. Franklin, Anne Baron Van Evercooren, Douglas A. Kerr. Stem cell transplantation in multiple sclerosis: current status and future prospects. Nat. Rev. Neurol. 2010 6, 247–255.
  • Trapp, B.D. et al. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 1998 338, 278–285
  • Freedman MS, Bar-Or A, Atkins HL, Karussis D, Frassoni F, Lazarus H, Scolding N, Slavin S, Le Blanc K, Uccelli A MSCT Study Group. Study Group The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group. Multiple Sclerosis. 2010 16(4) 503–510.
  • Karussis D, Karageorgiou C, Vaknin-Dembinsky A, Gowda-Kurkalli B, Gomori JM, Kassis I, Bulte JW, Petrou P, Ben-Hur T, Abramsky O, Slavin S. Safety and Immunological Effects of Mesenchymal Stem Cell Transplantation in Patients With Multiple Sclerosis and Amyotrophic Lateral Sclerosis. Arch Neurol. 2010 67(10):1187-1194.
  • Connick P1, Kolappan M, Crawley C, Webber DJ, Patani R, Michell AW, Du MQ, Luan SL, Altmann DR, Thompson AJ, Compston A, Scott MA, Miller DH, Chandran S. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet Neurol 2012 11: 150–56.
  • Llufriu S, Sepúlveda M, Blanco Y, Marín P, Moreno B, Berenguer J, Gabilondo I, Martínez-Heras E, Sola-Valls N, Arnaiz JA, Andreu EJ, Fernández B, Bullich S, Sánchez-Dalmau B, Graus F, Villoslada P, Saiz A. Randomized Placebo-Controlled Phase II Trial of Autologous Mesenchymal Stem Cells in Multiple Sclerosis. PLoS One. 2014 19(12).
  • Li JF, Zhang DJ, Geng T, Chen L, Huang H, Yin HL, Zhang YZ, Lou JY, Cao B, Wang YL. The Potential of Human Umbilical Cord-Derived Mesenchymal Stem Cells as a Novel Cellular Therapy for Multiple Sclerosis. Cell Transplant. 2014 23 Suppl 1.
  • Tyndall A, Walker UA, Cope A, Dazzi F, De Bari C, Fibbe W, Guiducci S, Jones S, Jorgensen C, Le Blanc K, Luyten F, McGonagle D, Martin I, Bocelli-Tyndall C, Pennesi G, Pistoia V, Pitzalis C, Uccelli A, Wulffraat N, Feldmann M. Immunomodulatory properties of mesenchymal stem cells: a review based on an interdisciplinary meeting held at the Kennedy Institute of Rheumatology Division, London, UK, 31 October 2005. Arthritis Research & Therapy 2007 9:301
  • Baraniak PR1, McDevitt TC. Stem cell paracrine actions and tissue regeneration. Regen Med. 2010 5(1):121-43
  • Chandran S, Hunt D, Joannides A, Zhao C, Compston A, Franklin RJ. Myelin repair: the role of stem and precursor cells in multiple sclerosis. Philos Trans R Soc Lond B Biol Sci. 2008 12363(1489):171-83.
  • Bollini S, Gentili C, Tasso R, Cancedda R. The Regenerative Role of the Fetal and Adult Stem Cell Secretome. J Clin Med. 2013 172(4):302-27
  • Yeo RWY, Lai RC, Tan KH Lim SK. Exosome: A Novel and Safer Therapeutic Refinement of Mesenchymal Stem Cell. Exosomes microvesicles. 2013, Vol. 1, 7.

  1. Georg Hansmann, Philippe Chouvarine, Franziska Diekmann, Martin Giera, Markus Ralser, Michael Mülleder, Constantin von Kaisenberg, Harald Bertram, Ekaterina Legchenko & Ralf Hass "Human umbilical cord mesenchymal stem cell-derived treatment of severe pulmonary arterial hypertension". Nature Cardiovascular Research volume 1, pages568–576 (2022).
  2. Murphy JM, Fink DJ, Hunziker EB, et al. Stem cell therapy in a caprine model of osteoarthritis . Arthritis Rheum. 2003;48:3464–74.
  3. Lee KB, Hui JH, Song IC, Ardany L, et al. Injectable mesenchymal stem cell therapy for large cartilage defects—a porcine model. Stem Cell. 2007;25:2964–71.
  4. Saw KY, Hussin P, Loke SC, et al. Articular cartilage regeneration with autologous marrow aspirate and hyaluronic acid: an experimental study in a goat model. Arthroscopy . 2009;25(12):1391–400.
  5. Black L, Gaynor J, Adams C, et al. Effect of intra-articular injection of autologous adipose-derived mesenchymal stem and regenerative cells on clinical signs of chronic osteoarthritis of the elbow joint in dogs. Vet Ther. 2008;9:192-200.
  6. Centeno C, Busse D, Kisiday J, et al. Increased knee cartilage volume in degenerative joint disease using percutaneously implanted, autologous mesenchymal stem cells. Pain Physician. 2008;11(3):343–53.
  7. Centeno C, Kisiday J, Freeman M, et al. Partial regeneration of the human hip via autologous bone marrow nucleated cell transfer: a case study. Pain Physician. 2006;9:253–6.
  8. Centeno C, Schultz J, Cheever M. Safety and complications reporting on the re-implantation of culture-expanded mesenchymal stem cells using autologous platelet lysate technique. Curr Stem Cell. 2011;5(1):81–93.
  9. Pak J. Regeneration of human bones in hip osteonecrosis and human cartilage in knee osteoarthritis with autologous adipose derived stem cells: a case series. J Med Case Rep. 2001;5:296.
  10. Kuroda R, Ishida K, et al. Treatment of a full-thickness articular cartilage defect in the femoral condyle of an athlete with autologous bone-marrow stromal cells. Osteoarthritis Cartilage. 2007;15:226–31.
  11. Emadedin M, Aghdami N, Taghiyar L, et al. Intra-articular injection of autologous mesenchymal stem cells in six patients with knee osteoarthritis. Arch Iran Med. 2012;15(7):422–8.
  12. Saw KY et al. Articular cartilage regeneration with autologous peripheral blood stem cells versus hyaluronic acid: a randomized controlled trial. Arthroscopy. 2013;29(4):684–94.
  13. Vangsness CT, Farr J, Boyd J, et al. Adult human mesenchymal stem cells delivered via intra-articular injection to the knee following partial medial meniscectomy. J Bone Joint Surg. 2014;96(2):90–8.
  14. Freitag, Julien, et al. Mesenchymal stem cell therapy in the treatment of osteoarthritis: reparative pathways, safety and efficacy–a review. BMC musculoskeletal disorders 17.1 (2016): 230.
  15. Maumus, Marie, Christian Jorgensen, and Danièle Noël. " Mesenchymal stem cells in regenerative medicine applied to rheumatic diseases: role of secretome and exosomes. " Biochimie 95.12 (2013): 2229-2234.
  16. Dostert, Gabriel, et al. " How do mesenchymal stem cells influence or are influenced by microenvironment through extracellular vesicles communication?. " Frontiers in Cell and Developmental Biology 5 (2017).
  17. Chaparro, Orlando, and Itali Linero. " Regenerative Medicine: A New Paradigm in Bone Regeneration. " (2016).
  18. Toh, Wei Seong, et al. " MSC exosome as a cell-free MSC therapy for cartilage regeneration: Implications for osteoarthritis treatment. " Seminars in Cell & Developmental Biology. Academic Press, 2016.
  19. Chaparro, Orlando, and Itali Linero. " Regenerative Medicine: A New Paradigm in Bone Regeneration. " (2016).
  20. S. Koelling, J. Kruegel, M. Irmer, J.R. Path, B. Sadowski, X. Miro, et al., Migratory chondrogenic progenitor cells from repair tissue during the later stages of human osteoarthritis , Cell Stem Cell 4 (2009) 324–335.
  21. B.A. Jones, M. Pei, Synovium-Derived stem cells: a tissue-Specific stem cell for cartilage engineering and regeneration , Tissue Eng. B: Rev. 18 (2012) 301–311.
  22. W. Ando, J.J. Kutcher, R. Krawetz, A. Sen, N. Nakamura, C.B. Frank, et al., Clonal analysis of synovial fluid stem cells to characterize and identify stable mesenchymal stromal cell/mesenchymal progenitor cell phenotypes in a porcine model: a cell source with enhanced commitment to the chondrogenic lineage, Cytotherapy 16 (2014) 776–788.
  23. K.B.L. Lee, J.H.P. Hui, I.C. Song, L. Ardany, E.H. Lee, Injectable mesenchymal stem cell therapy for large cartilage defects—a porcine model, Stem Cells 25 (2007) 2964–2971.
  24. W.-L. Fu, C.-Y. Zhou, J.-K. Yu, A new source of mesenchymal stem cells for articular cartilage repair: mSCs derived from mobilized peripheral blood share similar biological characteristics in vitro and chondrogenesis in vivo as MSCs from bone marrow in a rabbit model , Am. J. Sports Med. 42 (2014) 592–601.
  25. X. Xie, Y. Wang, C. Zhao, S. Guo, S. Liu, W. Jia, et al., Comparative evaluation of MSCs from bone marrow and adipose tissue seeded in PRP-derived scaffold for cartilage regeneration , Biomaterials 33 (2012) 7008–7018.
  26. E.-R. Chiang, H.-L. Ma, J.-P. Wang, C.-L. Liu, T.-H. Chen, S.-C. Hung, Allogeneic mesenchymal stem cells in combination with hyaluronic acid for the treatment of osteoarthritis in rabbits , PLoS One 11 (2016) e0149835.
  27. H. Nejadnik, J.H. Hui, E.P. Feng Choong, B.-C. Tai, E.H. Lee, Autologous bone marrow–derived mesenchymal stem cells versus autologous chondrocyte implantation: an observational cohort study , Am. J. Sports Med. 38 (2010) 1110–1116.
  28. I. Sekiya, T. Muneta, M. Horie, H. Koga, Arthroscopic transplantation of synovial stem cells improves clinical outcomes in knees with cartilage defects , Clin. Orthop. Rel. Res. 473 (2015) 2316–2326.
  29. Y.S. Kim, Y.J. Choi, Y.G. Koh, Mesenchymal stem cell implantation in knee osteoarthritis: an assessment of the factors influencing clinical outcomes , Am. J. Sports Med. 43 (2015) 2293–2301.
  30. W.-L. Fu, Y.-F. Ao, X.-Y. Ke, Z.-Z. Zheng, X. Gong, D. Jiang, et al., Repair of large full-thickness cartilage defect by activating endogenous peripheral blood stem cells and autologous periosteum flap transplantation combined with patellofemoral realignment , Knee 21 (2014) 609–612.
  31. Y.-G. Koh, O.-R. Kwon, Y.-S. Kim, Y.-J. Choi, D.-H. Tak, Adipose-derived mesenchymal stem cells with microfracture versus microfracture alone: 2-year follow-up of a prospective randomized trial , Arthrosc. J. Arthrosc. Relat. Surg. 32 (2016) 97–109.
  32. T.S. de Windt, L.A. Vonk, I.C.M. Slaper-Cortenbach, M.P.H. van den Broek, R. Nizak, M.H.P. van Rijen, et al., Allogeneic mesenchymal stem cells stimulate cartilage regeneration and are safe for single-Stage cartilage repair in humans upon mixture with recycled autologous chondrons , Stem Cells (2016) (n/a-n/a).
  33. L. da Silva Meirelles, A.M. Fontes, D.T. Covas, A.I. Caplan, Mechanisms involved in the therapeutic properties of mesenchymal stem cells , Cytokine Growth Factor Rev. 20 (2009) 419–427.
  34. W.S. Toh, C.B. Foldager, M. Pei, J.H.P. Hui, Advances in mesenchymal stem cell-based strategies for cartilage repair and regeneration , Stem Cell Rev. Rep. 10 (2014) 686–696.
  35. R.C. Lai, F. Arslan, M.M. Lee, N.S.K. Sze, A. Choo, T.S. Chen, et al., Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury , Stem Cell Res. 4 (2010) 214–222.
  36. S. Zhang, W.C. Chu, R.C. Lai, S.K. Lim, J.H.P. Hui, W.S. Toh, Exosomes derived from human embryonic mesenchymal stem cells promote osteochondral regeneration, Osteoarthr . Cartil. 24 (2016) 2135–2140.
  37. S. Zhang, W. Chu, R. Lai, J. Hui, E. Lee, S. Lim, et al., 21 – human mesenchymal stem cell-derived exosomes promote orderly cartilage regeneration in an immunocompetent rat osteochondral defect model , Cytotherapy 18 (2016) S13.
  38. C.T. Lim, X. Ren, M.H. Afizah, S. Tarigan-Panjaitan, Z. Yang, Y. Wu, et al., Repair of osteochondral defects with rehydrated freeze-dried oligo[poly(ethylene glycol) fumarate] hydrogels seeded with bone marrow mesenchymal stem cells in a porcine model
  39. A. Gobbi, G. Karnatzikos, S.R. Sankineani, One-step surgery with multipotent stem cells for the treatment of large full-thickness chondral defects of the knee , Am. J. Sports Med. 42 (2014) 648–657.
  40. A. Gobbi, C. Scotti, G. Karnatzikos, A. Mudhigere, M. Castro, G.M. Peretti, One-step surgery with multipotent stem cells and Hyaluronan-based scaffold for the treatment of full-thickness chondral defects of the knee in patients older than 45 years , Knee Surg. Sports Traumatol. Arthrosc. (2016) 1–8.
  41. A. Gobbi, G. Karnatzikos, C. Scotti, V. Mahajan, L. Mazzucco, B. Grigolo, One-step cartilage repair with bone marrow aspirate concentrated cells and collagen matrix in full-thickness knee cartilage lesions: results at 2-Year follow-up , Cartilage 2 (2011) 286–299.
  42. K.L. Wong, K.B.L. Lee, B.C. Tai, P. Law, E.H. Lee, J.H.P. Hui, Injectable cultured bone marrow-derived mesenchymal stem cells in varus knees with cartilage defects undergoing high tibial osteotomy: a prospective, randomized controlled clinical trial with 2 years’ follow-up , Arthrosc. J. Arthrosc. Relat. Surg. 29 (2013) 2020–2028.
  43. J.M. Hare, J.E. Fishman, G. Gerstenblith, et al., Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the poseidon randomized trial, JAMA 308 (2012) 2369–2379.
  44. L. Wu, J.C.H. Leijten, N. Georgi, J.N. Post, C.A. van Blitterswijk, M. Karperien, Trophic effects of mesenchymal stem cells increase chondrocyte proliferation and matrix formation , Tissue Eng. A 17 (2011) 1425–1436.
  45. L. Wu, H.-J. Prins, M.N. Helder, C.A. van Blitterswijk, M. Karperien, Trophic effects of mesenchymal stem cells in chondrocyte Co-Cultures are independent of culture conditions and cell sources , Tissue Eng. A 18 (2012) 1542–1551.
  46. S.K. Sze, D.P.V. de Kleijn, R.C. Lai, E. Khia Way Tan, H. Zhao, K.S. Yeo, et al., Elucidating the secretion proteome of human embryonic stem cell-derived mesenchymal stem cells , Mol. Cell. Proteomics 6 (2007) 1680–1689.
  47. M.B. Murphy, K. Moncivais, A.I. Caplan, Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine , Exp. Mol. Med. 45 (2013) e54.
  48. M.J. Lee, J. Kim, M.Y. Kim, Y.-S. Bae, S.H. Ryu, T.G. Lee, et al., Proteomic analysis of tumor necrosis factor--induced secretome of human adipose tissue-derived mesenchymal stem cells , J. Proteome Res. 9 (2010) 1754–1762.
  49. S. Bruno, C. Grange, M.C. Deregibus, R.A. Calogero, S. Saviozzi, F. Collino, et al., Mesenchymal stem cell-derived microvesicles protect against acute tubular injury, J. Am. Soc. Nephrol. 20 (2009) 1053–1067.
  50. M. Yá˜nez-Mó, P.R.-M. Siljander, Z. Andreu, A.B. Zavec, F.E. Borràs, E.I. Buzas, et al. Biological properties of extracellular vesicles and their physiological functions (2015).
  51. C. Lawson, J.M. Vicencio, D.M. Yellon, S.M. Davidson, Microvesicles and exosomes: new players in metabolic and cardiovascular disease , J. Endocrinol. 228 (2016) R57–R71.
  52. A.G. Thompson, E. Gray, S.M. Heman-Ackah, I. Mager, K. Talbot, S.E. Andaloussi, et al., Extracellular vesicles in neurodegenerative diseas—pathogenesis to biomarkers, Nat. Rev. Neurol. 12 (2016) 346–357.
  53. I.E.M. Bank, L. Timmers, C.M. Gijsberts, Y.-N. Zhang, A. Mosterd, J.-W. Wang, et al., The diagnostic and prognostic potential of plasma extracellular vesicles for cardiovascular disease , Expert Rev. Mol. Diagn. 15 (2015) 1577–1588.
  54. T. Kato, S. Miyaki, H. Ishitobi, Y. Nakamura, T. Nakasa, M.K. Lotz, et al., Exosomes from IL-1 stimulated synovial fibroblasts induce osteoarthritic changes in articular chondrocytes , Arthritis. Res. Ther. 16 (2014) 1–11.
  55. R.W.Y. Yeo, S.K. Lim, Exosomes and their therapeutic applications, in: C. Gunther, A. Hauser, R. Huss (Eds.), Advances in Pharmaceutical Cell TherapyPrinciples of Cell-Based Biopharmaceuticals, World Scientific, Singapore, 2015, pp. 477–491.
  56. X. Qi, J. Zhang, H. Yuan, Z. Xu, Q. Li, X. Niu, et al., Exosomes secreted by human-Induced pluripotent stem cell-derived mesenchymal stem cells repair critical-sized bone defects through enhanced angiogenesis and osteogenesis in osteoporotic rats , Int. J. Biol. Sci. 12 (2016) 836–849.
  57. R.C. Lai, F. Arslan, S.S. Tan, B. Tan, A. Choo, M.M. Lee, et al., Derivation and characterization of human fetal MSCs: an alternative cell source for large-scale production of cardioprotective microparticles , J. Mol. Cell. Cardiol. 48 (2010) 1215–1224.
  58. Y. Zhou, H. Xu, W. Xu, B. Wang, H. Wu, Y. Tao, et al., Exosomes released by human umbilical cord mesenchymal stem cells protect against cisplatin-induced renal oxidative stress and apoptosis in vivo and in vitro , Stem Cell Res. Ther. 4 (2013) 1–13.
  59. Y. Qin, L. Wang, Z. Gao, G. Chen, C. Zhang, Bone marrow stromal/stem cell-derived extracellular vesicles regulate osteoblast activity and differentiation in vitro and promote bone regeneration in vivo , Sci. Rep. 6 (2016) 21961.
  60. M. Nakano, K. Nagaishi, N. Konari, Y. Saito, T. Chikenji, Y. Mizue, et al., Bone marrow-derived mesenchymal stem cells improve diabetes-induced cognitive impairment by exosome transfer into damaged neurons and astrocytes , Sci. Rep. 6 (2016) 24805.
  61. K. Nagaishi, Y. Mizue, T. Chikenji, M. Otani, M. Nakano, N. Konari, et al., Mesenchymal stem cell therapy ameliorates diabetic nephropathy via the paracrine effect of renal trophic factors including exosomes , Sci. Rep. 6 (2016) 34842.
  62. S.R. Baglio, K. Rooijers, D. Koppers-Lalic, F.J. Verweij, M. Pérez Lanzón, N. Zini, et al., Human bone marrow- and adipose-mesenchymal stem cells secrete exosomes enriched in distinctive miRNA and tRNA species , Stem Cell Res. Ther. 6 (2015) 1–20.
  63. T. Chen, R. Yeo, F. Arslan, Y. Yin, S. Tan, Efficiency of exosome production correlates inversely with the developmental maturity of MSC donor, J. Stem Cell Res. Ther. 3 (2013) 2.
  64. R.C. Lai, S.S. Tan, B.J. Teh, S.K. Sze, F. Arslan, D.P. de Kleijn, et al., Proteolytic potential of the MSC exosome proteome: implications for an exosome-mediated delivery of therapeutic proteasome , Int. J. Proteomics 2012 (2012) 971907.
  65. T.S. Chen, R.C. Lai, M.M. Lee, A.B.H. Choo, C.N. Lee, S.K. Lim, Mesenchymal stem cell secretes microparticles enriched in pre-microRNAs , Nucleic Acids Res. 38 (2010) 215–224.
  66. R.W. Yeo, R.C. Lai, K.H. Tan, S.K. Lim, Exosome: a novel and safer therapeutic refinement of mesenchymal stem cell, J. Circ. Biomark. 1 (2013) 7.
  67. R.C. Lai, R.W. Yeo, S.K. Lim, Mesenchymal stem cell exosomes, Semin. Cell Dev. Biol. 40 (2015) 82–88.
  68. B. Zhang, R.W. Yeo, K.H. Tan, S.K. Lim, Focus on extracellular vesicles: therapeutic potential of stem cell-derived extracellular vesicles , Int. J. Mol. Sci. 17 (2016) 174.
  69. Hu G-w, Q. Li, X. Niu, B. Hu, J. Liu, Zhou S-m, et al., Exosomes secreted by human-induced pluripotent stem cell-derived mesenchymal stem cells attenuate limb ischemia by promoting angiogenesis in mice , Stem Cell Res. Ther. 6 (2015) 1–15.
  70. J. Zhang, J. Guan, X. Niu, G. Hu, S. Guo, Q. Li, et al., Exosomes released from human induced pluripotent stem cells-derived MSCs facilitate cutaneous wound healing by promoting collagen synthesis and angiogenesis , J. Transl. Med. 13 (2015) 1–14.
  71. B. Zhang, M. Wang, A. Gong, X. Zhang, X. Wu, Y. Zhu, et al., HucMSC-exosome mediated-Wnt4 signaling is required for cutaneous wound healing, Stem Cells 33 (2015) 2158–2168.
  72. B. Zhang, Y. Yin, R.C. Lai, S.S. Tan, A.B.H. Choo, S.K. Lim, Mesenchymal stem cells secrete immunologically active exosomes , Stem Cells Dev. 23 (2013) 1233–1244.
  73. C.Y. Tan, R.C. Lai, W. Wong, Y.Y. Dan, S.-K. Lim, H.K. Ho, Mesenchymal stem cell-derived exosomes promote hepatic regeneration in drug-induced liver injury models , Stem Cell Res. Ther. 5 (2014) 1–14.
  74. C. Lee, S.A. Mitsialis, M. Aslam, S.H. Vitali, E. Vergadi, G. Konstantinou, et al., Exosomes mediate the cytoprotective action of mesenchymal stromal cells on hypoxia-induced pulmonary hypertension , Circulation 126 (2012) 2601–2611.
  75. B. Yu, H. Shao, C. Su, Y. Jiang, X. Chen, L. Bai, et al., Exosomes derived from MSCs ameliorate retinal laser injury partially by inhibition of MCP-1 , Sci. Rep. 6 (2016) 34562.
  76. Jo CH, Lee YG, Shin WH, et al. Intra-articular injection of mesenchymal stem cells for the treatment of osteoarthritis of the knee: a proof of concept clinical trial. Stem Cells. 2014;32(5):1254–66.
  77. Vega, Aurelio, et al. Treatment of knee osteoarthritis with allogeneic bone marrow mesenchymal stem cells: a randomized controlled trial. Transplantation. 2015;99(8):1681–90.
  78. Davatchi F, Sadeghi-Abdollahi B, Mohyeddin M, et al. Mesenchymal stem cell therapy for knee osteoarthritis. Preliminary report of four patients. Int J Rheum Dis. 2011;14(2):211–5
  79. Hernigou P, Flouzat Lachaniette CH, Delambre J, et al. Biologic augmentation of rotator cuff repair with mesenchymal stem cells during arthroscopy improves healing and prevents further tears: a case- controlled study. Int Orthop. 2014;38(9):1811–1818
  80. Galli D, Vitale M, Vaccarezza M. Bone marrow-derived mesenchymal cell differentiation toward myogenic lineages: facts and perspectives. Biomed Res Int. 2014;2014:6.
  81. Beitzel K, Solovyova O, Cote MP, et al. The future role of mesenchymal Stem cells in The management of shoulder disorders . Arthroscopy. 2013;29(10):1702–1711.
  82. Isaac C, Gharaibeh B, Witt M, Wright VJ, Huard J. Biologic approaches to enhance rotator cuff healing after injury. J Shoulder Elbow Surg. 2012;21(2):181–190.
  83. Malda, Jos, et al. " Extracellular vesicles [mdash] new tool for joint repair and regeneration. " Nature Reviews Rheumatology (2016).

  1. Xu, Ming, et al. " Transplanted senescent cells induce an osteoarthritis-like condition in mice. " The Journals of Gerontology Series A: Biological Sciences and Medical Sciences (2016): glw154.
  2. McCulloch, Kendal, Gary J. Litherland, and Taranjit Singh Rai. " Cellular senescence in osteoarthritis pathology ." Aging Cell (2017).

Contraindications

Our stem cell treatments are experimental, but we only treat patients for whom we believe the risk/benefit ratio indicates treatment based on the state of the art, i.e., medical, scientific evidence.

Please understand that we therefore do not treat patients for whom the following points apply:

  • Active cancer in the last two years
  • Not yet of legal age
  • Existing pregnancy or lactation period
  • Unable to breathe on own, ventilator
  • Difficulty breathing in supine position
  • Dysphagia (extreme difficulty swallowing)
  • Psychiatric disorder
  • Active infectious disease (Hepatitis A, B, C, HIV, Syphilis, or other)